Cancer Epigenetics for the 21st Century: What's Next?
- PMID: 21941616
- PMCID: PMC3174266
- DOI: 10.1177/1947601911423096
Cancer Epigenetics for the 21st Century: What's Next?
Abstract
The discovery of global DNA hypomethylation events in human tumors in the early 1980s and the identification of CpG island promoter hypermethylation of tumor suppressor genes in cancer cells in the mid 1990s opened the door to the current excitement about the contribution of epigenetic disruption to human disease. The recent gigantic advances in technology make it possible to obtain complete DNA methylomes, histonomes, and non-coding RNA transcriptomes for many biological settings and their associated disorders. Furthermore, whole genome sequencing analyses yields an increasing number of mutated epigenetic genes in neoplasia. It is time to sit back, enjoy the show with a little help of friendly bioinformatic tools, and wonder about what will happen next.
Keywords: DNA methylation; cancer; epigenetics; histone; microRNA.
References
-
- Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature. 2007;447:433-40 - PubMed
-
- Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011;17:330-9 - PubMed
-
- Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-4 - PubMed
LinkOut - more resources
Full Text Sources